Clinical Practice Guidelines for Dementia: Recommendations for the Pharmacological Treatment of Behavioral and Psychological Symptoms

作者：Gihwan Byeon, Dong Woo Kang, Yeshin Kim, Geon Ha Kim, Ko Woon Kim, Han Jo Kim, Seunghee Na, Kee Hyung Park, Young Ho Park, Jeewon Suh, Joon Hyun Shin, YongSoo Shim, YoungSoon Yang, Yoo Hyun Um, Seong‐il Oh, Sheng‐Min Wang, Bora Yoon, Sun Min Lee, Juyoun Lee, Jin San Lee, Hak Young Rhee, Jae‐Sung Lim, Young Hee Jung, Juhee Chin, Hyemin Jang, Yun Jeong Hong, Miyoung Choi, Jae‐Won Jang · 发表于：Dementia and Neurocognitive Disorders · 年份：2025 · DOI：10.12779/dnd.2025.24.1.24 · 被引用次数：14 · 研究领域：Dementia and Cognitive Impairment Research、Healthcare and Venom Research、Neurological Disorders and Treatments

Background and Purpose: Dementia often accompanies behavioral and psychological symptoms of dementia (BPSD), including agitation, aggression, depression, and psychosis, which impact patients' quality of life and caregiver burden. Effective management of BPSD is essential to support patient and caregiver well-being. This study presents evidence-based clinical practice guidelines for pharmacological treatments of BPSD in dementia, focusing on antipsychotics, antidepressants, cognitive enhancers, and other medications. Methods: This guideline was developed by the Korean Dementia Association's Quality Management Committee. Key questions were framed using the Population, Intervention, Comparison, Outcome methodology, followed by systematic literature searches. Randomized controlled trials were assessed for quality, and recommendations were graded based on evidence levels, employing the Grading of Recommendations, Assessment, Development and Evaluation system to establish strength and applicability. Results: Recommendations vary by medication type and symptom severity. Antipsychotics, such as risperidone, are conditionally recommended for managing aggression and psychosis in dementia, while antidepressants, specifically citalopram, are advised for agitation in Alzheimer's disease. Cognitive enhancers, including cholinesterase inhibitors and memantine, showed moderate efficacy for general BPSD improvement and rapid eye movement sleep behavior disorder in Lewy body dementia. Specific...